CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.
Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.
In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).
Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
Your name *
First Last
Lippke

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
Jacobs University Bremen, Bremen, Germany

Your e-mail address *
abc@gmail.com
s.lippke@jacobs-university.de

Title of your manuscript *
Provide the (draft) title of your manuscript.

"Adherence with online therapy vs. face-to-face therapy and online therapy vs. care-as-usual: Secondary analysis of two randomized controlled trials"

Name of your App/Software/Intervention *
If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

ONL1 and ONL2
access is free and open
access only for special user groups, not open
access is open to everyone, but requires payment/subscription/in-app purchases
app/intervention no longer accessible
Sonstiges:
Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

*Indivduals had been admitted to rehabilitation

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

retention/dropout and adherence

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

satisfied with treatment, relationship satisfaction and success satisfaction

Recommended "Dose" *

What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Sonstiges:
Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Sonstiges:

Overall, was the app/intervention effective? *

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Sonstiges:
Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Sonstiges:

Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Sonstiges:
Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- [ ] Pilot/feasibility
- [x] Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- [ ] no ms number (yet) / not (yet) submitted to / published in JMIR
- [x] Sonstiges: 31274

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

- [ ] yes
- [ ] Sonstiges:
1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 1a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

online therapy vs. face-to-face therapy and online therapy vs. care-as-usual

1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Adherence with online therapy vs. face-to-face therapy and online therapy vs. care-as-usual: Secondary analysis of two randomized controlled trials"
1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., “for children with Type I Diabetes”)
Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions
NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT
Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
Does your paper address subitem 1b-i? *
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

in this paper, we were focusing on retention and adherence in F2F vs. online vs. CAU

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT
Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1  2  3  4  5

subitem not at all important   ○  ○  ☐  ○  ○  essential

Does your paper address subitem 1b-ii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"comparison between online with face-to-face (F2F) and care as usual (CAU)"
1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed user group trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use “blinded” or “unblinded” to indicate the level of blinding instead of “open”, as “open” in web-based trials usually refers to “open access” (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"N = 6,023 patients were recruited at their psychosomatic rehabilitation clinic."

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Results: There were no significant differences between the groups with regard to dropout rates over time ($\chi^2=0.02-1.06$, $P\geq.30$). Regarding adherence to the treatment condition, the online group outperformed the F2F condition with 3-6% and the CAU condition with 14-32% ($P\leq.01$). Within study arms gender differences were significant only in the CAU group at T2, with women being more likely to dropout (84% vs. 59% remaining in the study). At T3, age (dropouts were 8 years older) and marital status (80% of those who remained in the study were married whereas only 35% of the dropouts were married) were not significant in the online or F2F group ($P>.06$).

Patients in the online therapy were significantly more satisfied with their treatment than patients in the F2F group ($P=.022$; $\text{Eta}^2=.09$). Relationship satisfaction and success satisfaction were equally high ($P>.30$; $\text{Eta}^2=.02-.03$).

Combining all study arms, patients who reported lower depressiveness scores at T1 (OR=0.55-.56) were more likely to be retained, and patients who had higher self-efficacy (OR=0.52-0.57) were more likely to drop out. Additionally, at T3 the lower social support patients reported was related to a higher likelihood of remaining in the study (OR=0.68-0.79).

Positive expectation was significantly related to questionnaire completion at T2 and T3 (OR=1.59-1.64; $P=.02-0.05$).

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important ◯ ◯ ◯ ● ◯ essential

Auswahl löschen
Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Conclusions: While online interventions have many advantages to F2F variants such as saving time and effort to commute to the therapy, they also creating difficulties for therapists and hindering their ability to adequately react to patients’ challenges. Accordingly, patient characteristics which might put them at risk for dropping out or not adhering to the treatment plan should be considered in future research and practice."

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

1 2 3 4 5

subitem not at all important 〇 〇 〇 〇 〇 essential

Auswahl löschen
However, few studies have compared a human-delivered online therapy group with a control group with the same therapeutic techniques delivered in a face-to-face (F2F) format, and a treatment/care as usual group (CAU). So far, one study out of the few pre-existing studies found an advantage of the online therapy treatment over the CAU, and about the same effects as the F2F format [9]. The current research aims to use the data from this previous study for a secondary data analysis to further investigate adherence to the treatment arm, dropout from the study within the German Pension Insurance's framework concept for rehabilitation therapy [10], and the subjective evaluation of relationship, success and satisfaction.

2a-ii) Scientific background, rationale: What is known about the (type of) system
Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5
subitem not at all important essential

Auswahl löschen

Does your paper address subitem 2a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see Introduction "Prior work on study dropout and adherence
Expansive knowledge already exists on factors affecting study participants, the likelihood of questionnaire completion (eg, [6]), and adherence to the assigned

2b) In INTRODUCTION: Specific objectives or hypotheses
METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"If they agreed to participate, the rehabilitants who had an (F2F) therapy offer within a 45 min radius of their place of residence were randomly assigned to either the F2F therapy or the online therapy within the equivalence study (Fig. 1). Those without therapy offers in their vicinity were randomly assigned to online therapy or to no therapy offer within the so-called superiority study. 253 rehabilitants were assigned to one of the two study arms via the above-mentioned query. For the equivalence study, 142 rehabilitants were included in online therapy or F2F follow-up; and 111 rehabilitants were assigned to online therapy or the control group (care as usual) for the superiority study (Fig. 1)."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Does your paper address CONSORT subitem 3b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

no such changes had to be applied

3b-i) Bug fixes, Downtimes, Content Changes
Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

1  2  3  4  5
subitem not at all important ○ ○ ● ○ ○ essential

Does your paper address subitem 3b-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

does not apply to this study as we focussed on retention and adherence

4a) Eligibility criteria for participants
Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see figure 1 and "N = 6,023 patients were recruited at their psychosomatic rehabilitation clinic. After excluding non-eligible patients, n = 300 completed the baseline measures (T1). All rehabilitants who had participated in a psychotherapeutic rehabilitation treatment with Dr. Becker Klinik Möhnesee (March 2017 to May 2018), Dr. Becker Klinik Juliana (March 2017 to April 2018), and Dr. Becker Burgklinik (complete period between March 2017 and September 2020) were eligible for the aftercare therapy offer following the rehabilitation program."

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Auswahl löschen

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

this was checked by the clinic but not further included as not main focus
4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

1 2 3 4 5

- subitem not at all important
- essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks 'like this' to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

*N = 6,023 patients were recruited at their psychosomatic rehabilitation clinic. After excluding non-eligible patients, n = 300 completed the baseline measures (T1). All rehabilitants who had participated in a psychotherapeutic rehabilitation treatment with Dr. Becker Klinik Möhnesee (March 2017 to May 2018), Dr. Becker Klinik Juliana (March 2017 to April 2018), and Dr. Becker Burgklinik (complete period between March 2017 and September 2020) were eligible for the aftercare therapy offer following the rehabilitation program. Rehabilitants were questioned during their stay by a member of the social services staff and asked whether they wanted to take advantage of an aftercare therapy offer. If they said yes, they were informed about the option of participating in the study and about the study conditions.*

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

1 2 3 4 5

- subitem not at all important
- essential

Auswahl löschen
Does your paper address subitem 4a-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All participants were informed about the purpose of the study (including information on the length of the questionnaires and data storage procedures) via a participant information form and an informed consent form..."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"N = 6,023 patients were recruited at their psychosomatic rehabilitation clinic. After excluding non-eligible patients, n = 300 completed the baseline measures (T1). All rehabilitants who had participated in a psychotherapeutic rehabilitation treatment with Dr. Becker Klinik Möhnesee (March 2017 to May 2018), Dr. Becker Klinik Juliana (March 2017 to April 2018), and Dr. Becker Burgklinik (complete period between March 2017 and September 2020) were eligible for the aftercare therapy offer following the rehabilitation program."

4b-i) Report if outcomes were (self-)assessed through online questionnaires
Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important |   |   |   |   | essential |

Auswahl löschen
Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The survey was conducted during the rehabilitation by means of questionnaire measures at baseline (T1), 9 (superiority study) or 12 (equivalence study) months after the end of rehabilitation (after completion of the therapy intervention), and 15 (superiority study) or 18 (equivalence study) months after the end of rehabilitation. The reason for the postponed survey in the equivalence study was the waiting time for an aftercare place in the F2F therapy. The study participants were asked to fill out the T2 and T3 questionnaires by email and were reminded 2 and 4 weeks later, respectively. The questionnaires were filled out digitally via the platform soscisurvey.de. At T2 and T3, the rehabilitates were asked whether they really followed the study protocol in terms of adhering to the study arm and its therapy as they were assigned to."

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

1 2 3 4 5

subitem not at all important ○ ○ ● ○ ○ essential

Auswahl löschen

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

the whole study took place within the Dr. Becker clinic group and with the described hospitals.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Dr. Becker Clinic Group to which the recruiting hospitals belong

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
the therapeutic method was Curriculum Hannover "comparison of the same aftercare delivered via the internet (content and procedure of the therapy; Curriculum Hannover [21, 22]) compared to F2F and care-as-usual in terms of study dropout and intervention withdrawal. Thus, this will be the main aim of the current study, since the usefulness of Curriculum Hannover was tested before and clearly revealed its superiority to care-as-usual, as well as parity between the internet and F2F delivery methods [9]."

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

1 2 3 4 5

subitem not at all important ○ ○ ◉ ○ ○ essential

Auswahl löschen
Implementation of therapy
The therapy in the usual F2F contact was based on the concept from the Curriculum Hanover [21, 22], an aftercare treatment following the medical rehabilitation. Apart from the admission and final interviews, which were each a 50-minute individual interview, therapy took place over 25 weekly 90-minute group sessions with 8-10 participants. The online aftercare was carried out according to the same concept, but had technical peculiarities due to the digital format: the participants were instructed in advance on how to use the video platform by means of a learning video; this included, among other things, the rules for communication in the "virtual group room" as well as instructions for regularly checking the digital line. The psychotherapists prepared for the special features of the new format through training courses geared to equip them to build a therapeutic relationship in a targeted manner and to teach them how to use the video platform. Apart from group discussions, psychoeducation within the aftercare was conveyed by the therapists using PowerPoint presentations or a whiteboard. Handouts or homework could also be distributed. Under study conditions, care-as-usual therapy meant that no standardized therapy measures were initiated. Whether the participants of this study arm independently took

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important |   |   |   |   | essential |

not applicable as not main focus of this study
5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable as not main focus of this study

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.
Does your paper address subitem 5-vi?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable as not main focus of this study

5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all important  ○  ○  ○  ○  ◼ essential

Does your paper address subitem 5-vii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Data Exclusion
Inclusion criteria included indication for psychosomatic therapy (indication is determined by the procedure described in the German Pension Insurance's framework concept for rehabilitation therapy [10]) and access to a standard PC, tablet or smartphone with Internet access (DSL or LTE).
The exclusion criteria were also based on the framework concept for rehabilitation therapy of the German Pension Insurance and included employability <3 hours/day on the general labor market, drawing or applying for an old-age pension of at least two-thirds of the full-time pension, and drawing a benefit that is paid regularly until the start of a pension due to old age. Furthermore, patients with acute psychosomatic disorders are excluded."
5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback” [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Online vs. F2F and CAU, see above

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.
Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable as not main focus of this study

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
|   |   |   |   |   |
| subitem not at all important |   |   |   |   | essential |

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
|   |   |   |   |   |
| subitem not at all important |   |   |   |   | essential |

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

all therapies were human delivered, just the mode varied

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
|   |   |   |   |   |
| subitem not at all important |   |   |   |   | essential |

Auswahl löschen
Does your paper address subitem 5-xi? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study participants were asked to fill out the T2 and T3 questionnaires by email and were reminded 2 and 4 weeks later, respectively."

5-xii) Describe any co-interventions (incl. training/support)
Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 5-xii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The online aftercare was carried out according to the same concept, but had technical peculiarities due to the digital format: the participants were instructed in advance on how to use the video platform by means of a learning video; this included, among other things, the rules for communication in the "virtual group room" as well as instructions for regularly checking the digital line. The psychotherapists prepared for the special features of the new format through training courses geared to equip them to build a therapeutic relationship in a targeted manner and to teach them how to use the video platform. Apart from group discussions, psychoeducation within the aftercare was conveyed by the therapists using PowerPoint presentations or a whiteboard. Handouts or homework could also be distributed."

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

in this study, we only evaluated retention/dropout, adherence and satisfaction

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1  2  3  4  5

subitem not at all important  ○  ○  ○  ●  ○  essential

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

See section "Survey instruments
The following items were analyzed in the current longitudinal study..."

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1  2  3  4  5

subitem not at all important  ●  ○  ○  ○  ○  essential

 Auswählen löschen

?
Does your paper address subitem 6a-ii?
Copy and paste relevant sections from manuscript text

not relevant for this study

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

1 2 3 4 5
subitem not at all important ○ ○ □ ○ ○ essential

Does your paper address subitem 6a-iii?
Copy and paste relevant sections from manuscript text

not main focus of this study

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not main focus of this study

7a) How sample size was determined
NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed
7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important | ☐ | ☐ | ☐ | ☐ | ☐ |
| essential | ☐ | ☐ | ☐ | ☐ | ☐ |

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Power
To determine the minimum required sample size through a priori analysis for obtaining a significant medium effect size, we used PADD 11 software and G*Power 3 software (Psychonomic Society, Inc) [23, 24]. With regard to the superiority study and based on the assumption of an effect of the intervention of Cohen's d > .60 (> 8 points difference in primary end point), a total of 90 subjects (45 per study-arm) were needed to conduct the study at alpha < .05 and power > .80. Concerning the equivalence study and based on the assumption of an equivalence margin of Cohen's d < .29 (< 4 points difference in primary end point), a total of 410 subjects (205 per study arm) were planned for the study to test with at alpha < .05 and power > .80 [21 22]."

Does your paper address CONSORT subitem 7b?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

does not apply as we were explicitly interested in dropout prediction

7b) When applicable, explanation of any interim analyses and stopping guidelines

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group
There were 300 participants randomized into two RCTs: equivalence study (n = 167, left hand side in Tab. 1) and superiority study (n = 133, right hand side in Tab. 1).

**8b) Type of randomisation; details of any restriction (such as blocking and block size)**

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

does not apply in this study

**9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned**

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

does not apply in this study

**10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions**
Does your paper address CONSORT subitem 10? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not main focus of this study

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn’t
Specify who was blinded, and who wasn’t. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

subitem not at all important  ○ ○ ○  ○  ○  essential

Does your paper address subitem 11a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

blinding was not possible
11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”.

study arm was obvious to patients

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

"The online aftercare was carried out according to the same concept, but had technical peculiarities due to the digital format"

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed
12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in eHealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

Subitem not at all important

1 2 3 4 5

essential

was done in the primary paper but not in this study
12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

with some analyses, CAU was left out

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

subitem not at all important  ○  ○  ○  ○  ☑️  essential

Does your paper address subitem X26-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study protocol was approved by the Ethics Committee of the North Rhine Medical Association (Ärztekammer Nordrhein; No. 2015351 with Dec 4, 2015)."
x26-ii) Outline informed consent procedures
Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
Auswahl löschen

Does your paper address subitem X26-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All participants were informed about the purpose of the study (including information on the length of the questionnaires and data storage procedures) via a participant information form and an informed consent form"

x26-iii) Safety and security procedures
Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
Auswahl löschen

Does your paper address subitem X26-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

was reported in primary paper
RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

within the 2 studies, randomization was performed

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

yes, see Figure 1 and regarding text
13b-i) Attrition diagram
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

Does your paper address subitem 13b-i?
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

main focus of this paper as we were explicitly interested in attrition i.e. retention

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Table 1 "Note. T1, baseline time point measurement. T2, 9-months follow-up time point measurement for equivalence study, 12-months follow-up for superiority study. T3, 15-months follow-up for equivalence study, 18-months follow-up time point measurement for superiority study. ONL1: Online therapy in equivalence study; F2F = Face-to-face therapy in equivalence study; ONL2 = Online therapy in superiority study; CAU = Care as usual in superiority study."
14a-i) Indicate if critical “secular events” fell into the study period
Indicate if critical “secular events” fell into the study period, e.g., significant changes in Internet resources available or “changes in computer hardware or Internet delivery resources”

1 2 3 4 5
subitem not at all important ● ○ ○ ○ ○ essential

Auswahl löschen

Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
did not apply to this study

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
no, this did not happen as patients could stay or drop out

15) A table showing baseline demographic and clinical characteristics for each group
NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group
Does your paper address CONSORT subitem 15? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see Table 3. The differences between patients who completed the study and who dropout at T2.

15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 15-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not focus of this study as we focussed on retention and adherence

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not focus of this study as we focussed on retention and adherence

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not focus of this study as we focussed on retention and adherence
17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

predicting retention, we did that

17a-i) Presentation of process outcomes such as metrics of use and intensity of use
In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

Does your paper address subitem 17a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not focus of this study as we focussed on retention and adherence

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended
18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 17b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

effect sizes are reported in tables

Does your paper address CONSORT subitem 18? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not focus of this study as we focussed on retention and adherence

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

1  2  3  4  5

subitem not at all important  ○  ○  ●  ○  ○  essential

Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

we focussed on retention as ran accoding analyses
19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

there was a close supervision the patients

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | 〇 | 〇 | 〇 | 〇 | 〇 | essential

Does your paper address subitem 19-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not focus of this study as this would go too far
19-ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 19-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

this was a quantitative study only

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Auswahl löschen
Does your paper address subitem 22-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

we explicitly answered all research questions

22-ii) Highlight unanswered new questions, suggest future research
Highlight unanswered new questions, suggest future research.

subitem not at all important  ○  ○  ○  ○  ● essential

Does your paper address subitem 22-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

e.g., "However, these assumptions need to be researched further in the future and in more detail."
"Thus, our study evaluated the intervention over a relatively long time frame and more studies like this are required in the future to replicate our findings with larger samples."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

1  2  3  4  5

subitem not at all important  ☐  ☐  ☑  ☐  ☐  essential

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The present study was designed to investigate online therapies with F2F therapy and care as usual in terms of symptom improvement. One main limitation was that the care as usual group was not assessed regarding their expectations due to practical and ethical considerations. Another limitation was the fact that dropouts were not specifically re-assessed because this was not planned with the study protocol [9]. However, further prospective and randomized studies are necessary to investigate the actual acceptance of online therapy opportunities and the prevention of dropout from (online) therapies and measurement points. Additionally, testing whether a tailoring to the expectations and resources of the patients would be worthwhile, specifically with regard to dropout and non-adherence."

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial.

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations.

1  2  3  4  5

subitem not at all important  ☐  ☐  ☑  ☐  ☐  essential
Does your paper address subitem 21-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

this would go too far but of course would be an important topic.

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting
Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

[5-star rating] essential

CAU was explicitly use for this purpose

OTHER INFORMATION

23) Registration number and name of trial registry
24) Where the full trial protocol can be accessed, if available

"Trial Registration: The trial was planned to be registered at the German Clinical Trials Register (Deutsches Register Klinischer Studien, DRKS) and the study protocol was published at XXX" (blinded for peer review)

25) Sources of funding and other support (such as supply of drugs), role of funders

blinded: "The Open Access Fee was provided by the XXX. The XXX had no role in the study design, study implementation, data collection, data analysis, manuscript preparation, or publication decision. The work is the responsibility of the authors."

X27) Conflicts of Interest (not a CONSORT item)
X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1 2 3 4 5

subitem not at all important ◯ ◯ ◯ ◯ ◯ essential

About the CONSORT EHEALTH checklist

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

We report affiliations with Alina Dahmen and Petra Becker being employees of the clinic group providing the rehab an aftercare.

As a result of using this checklist, did you make changes in your manuscript? *

○ yes, major changes

○ yes, minor changes

○ no

What were the most important changes you made as a result of using this checklist?

explicit reporting of the items
How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

- approximately 20 hours but difficult to say

As a result of using this checklist, do you think your manuscript has improved? *

- yes
- no
- Sonstiges:

Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an “Explanation and Elaboration” document

- yes
- no
- Sonstiges:

Any other comments or questions on CONSORT EHEALTH

Meine Antwort

STOP - Save this form as PDF before you click submit
To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select “print” and then select “print as PDF”) before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!
Final step: Click submit!
Click submit so we have your answers in our database!